retatrutide type 2 diabetes trial is gaining attention in metabolic research for its triple agonist activity on GIP, GLP-1, and glucagon receptors. In this carousel, we summarize recent clinical study findings related to weight management, Retatrutide, a GIP, GLP-1 and

Based on their duration of action, they are classified as short-acting or long-acting

Step 2: Download The App Talk, Text, or Video chat with your Miramont Physician any time, from anywhere

Gradual weight loss of 12 pounds per week allows the dermis to remodel progressively, reducing the severity of skin laxity

Aspirin may retain a role in select inflammatory or hereditary risk settings, while GLP-1 agents could become foundational for metabolically driven risk reduction

These features make GLP-1 RAs an advantageous alternative to rapid-acting insulin for patients inadequately controlled on a long-acting basal insulin